BioSpace News Archive

Lyndra Therapeutics today announced the appointment of two new members of its Board of Directors: Doug Dachille, former Chief Investment Officer of American International Group, Inc.

Humacyte, Inc. today announced the issuance of three additional U.S. patents covering its proprietary technology platform.

Neurelis, Inc. announced today that it has initiated a clinical program to investigate the use of VALTOCO® (diazepam nasal spray) in children with epilepsy aged two to five as a treatment for seizure clusters.

Vaccination against SARS2-COVID was initially efficient at slowing down viral spreading across the globe.

Alvotech, a multinational biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets, today announced that the FDA is deferring action on the application for AVT02, the company’s proposed biosimilar to Humira®, until facility assessments can be completed.

The U.S. Food and Drug Administration today approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.

A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. today announced that Judge Maryellen Noreika has approved a joint stipulation to dismiss CYDY’s lawsuit in the United States District Court for the District of Delaware.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the publication of a research paper in Nature Metabolism, which showed for the first time that restoring normal function of the mesenteric lymphatics may reverse insulin resistance and modify obesity-associated metabolic disease.

The studies proposed in this grant aim to address several clinical challenges for dental implant therapy, especially in patients with low bone density conditions such as osteoporosis.

Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX® (cabozantinib) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).